Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−148.73 MXN
−8.53 B MXN
8.20 B MXN
59.40 M
About Ascendis Pharma A/S
Sector
CEO
Jan Møller Mikkelsen
Headquarters
Hellerup
Website
Founded
2006
FIGI
BBG00JX0QX19
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange ASCENDIS PHARMA A/S stocks are traded under the ticker ASND/N.
ASND/N stock has risen by 3.17% compared to the previous week, the month change is a 3.17% rise, over the last year ASCENDIS PHARMA A/S has showed a 3.17% increase.
We've gathered analysts' opinions on ASCENDIS PHARMA A/S future price: according to them, ASND/N price has a max estimate of 5,885.38 MXN and a min estimate of 3,300.64 MXN. Watch ASND/N chart and read a more detailed ASCENDIS PHARMA A/S stock forecast: see what analysts think of ASCENDIS PHARMA A/S and suggest that you do with its stocks.
ASND/N stock is 3.17% volatile and has beta coefficient of 0.78. Track ASCENDIS PHARMA A/S stock price on the chart and check out the list of the most volatile stocks — is ASCENDIS PHARMA A/S there?
Today ASCENDIS PHARMA A/S has the market capitalization of 188.20 B, it has decreased by −2.19% over the last week.
Yes, you can track ASCENDIS PHARMA A/S financials in yearly and quarterly reports right on TradingView.
ASCENDIS PHARMA A/S is going to release the next earnings report on May 21, 2025. Keep track of upcoming events with our Earnings Calendar.
ASND/N earnings for the last quarter are −13.81 MXN per share, whereas the estimation was −21.18 MXN resulting in a 34.79% surprise. The estimated earnings for the next quarter are −31.84 MXN per share. See more details about ASCENDIS PHARMA A/S earnings.
ASCENDIS PHARMA A/S revenue for the last quarter amounts to 3.75 B MXN, despite the estimated figure of 2.58 B MXN. In the next quarter, revenue is expected to reach 2.03 B MXN.
ASND/N net income for the last quarter is −855.55 M MXN, while the quarter before that showed −2.15 B MXN of net income which accounts for 60.15% change. Track more ASCENDIS PHARMA A/S financial stats to get the full picture.
No, ASND/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ASCENDIS PHARMA A/S EBITDA is −5.91 B MXN, and current EBITDA margin is −71.79%. See more stats in ASCENDIS PHARMA A/S financial statements.
Like other stocks, ASND/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASCENDIS PHARMA A/S stock right from TradingView charts — choose your broker and connect to your account.